update, page-18

The big mystery for me with todays "March 2012 Update" was also the announcement title, itself, combined with other parts of Glyn's brief offering, which I have highlighted with red text, among some other comments in this post:

"The Company updates Shareholders on its activities during the reporting period ended 31 March 2012"

I remain somewhat curious as to why the company decided to provide this update today, and I do agree with others that it does appear to be prepared in haste, although we do have over 4,000 share holders, so perhaps this was Glyn's idea to help clear his inbox?
___

Global FMCG
"Negotiations and discussions with the global FMCG, previously announced by the Company are proceeding to the satisfaction of the Company. OBJ’s technical team is working with their international brand groups to determine the scope of the collaborative development programs going forward."

Other than using the term, "Global FMCG" there was no reference to "JDA" or "Beauty Care" so how can we be sure which FMCG Company he might be refering to?

Was it this Global FMCG Company announced in Feb 2010, or was he refering to this Global FMCG Company announced in September 2010, which he stated was a, new relationship for the company, and is in addition to other programs and collaborations in the Fast Moving Consumer Goods (FMCG) sector previously announced"...

Assuming his reference was relating to our JDA negotiating FMCG partner, we could also ask why an update for the other FMCG partners, and the Major US Pharma in multi-product discussions with OBJ was also omitted from this update?

FMCG 1 (USA)?
FMCG 2 (UK)?
FMCG 3 (Global)?
Major US Pharma?

Glyn certainly didn't want to ring any bells today, imo. ;)
___

GSK
"The Company is pleased to report that the work with GSK in the field of oral health is proceeding with a view to expanding the scope of the current collaboration to include additional key oral health active ingredients. A number of study programs are currently being planned.

During the quarter the relationship with GSK was expanded to include discussions with the GSK Pharmaceutical groups in the US."

GSK = Expansion + Expansion + Expansion

1. "...to include additional key oral health actives"
2. "A number of study programs currently being planned"
3. "discussions with GSK Pharmaceutical groups in the US"

I'm definitely looking forward to the next announcement providing more detailed information with our GSK partnership.
___

Micro-needles
"The Company has been working with the University of Queensland and in particular Dr Tarl Prow in the development of enhancing micro-needle performance with the addition of OBJ’s ETP magnetic technology. OBJ’s ETP technology, when integrated into a traditional micro needle delivery system, showed substantially greater drug delivery than micro-needles alone. The resulting technology was the subject of a recent patent application and the results of that work were presented at the PPP Drug delivery Conference in France early in the month by OBJ Director, Dr Chris Quirk."

"A number of commercial opportunities are now being explored following the scientific presentation."

Q: What was the title of todays announcement again and can someone remind me what reporting period this update was said to cover... March or April ;)

"...results of that work were presented at the PPP Drug delivery Conference in France early in the month by OBJ Director, Dr Chris Quirk."

PPP Thirteenth International Conference - 11-14 April 2012

PROGRAM PPP 2012 - THURSDAY 12th April @ 14:15pm: Chris Quirk: Enhanced microneedle delivery by magnetic microarrays

The reason I highlight this is because, as this update does provide one piece of news activity for the month of April, why wasn't the update simply titled, April Update? What activities have been taking form during the month of April that have been intentionally omitted from this ambiguously titled, "March Update"

I don't have the answer to this question, but I suspect that it is probably not too far away...
___

Anyway, back to the information announced today, Glyn, today has kindly confirmed that; University of Queensland + Dr Tarl Prow + OBJ = Micro-needles

Tarl Prow's Overview
Chief Investigator at University of Queensland

"I have established programs for developing micro- and nano-delivery platforms and cutting-edge non-invasive imaging."

Projects
"Over the past few years, my collaborators and I developed microneedle-based drug and vaccine delivery to treat and/or prevent cancers. The development of novel nanolayered microneedles will help us deliver therapeutic/diagnostic nanoparticles to site of interest. Over the last year, I have used edge-cutting non-invasive imaging, such as reflectance confocal microscopy and fluorescence lifetime imaging microscopy, to identify the therapeutics uses for silver nanoparticles by analysing the metabolic effects of skin in volunteers. In addition, I have studied the penetration of quantum dots and nanotoxicology of metal nanoparticles in human skin metabolism using advanced time correlated single photon counting techniques."

Specialties

"Micromedical devices, nanomedicines, nanotoxicology, drug delivery, non-invasive imaging, multiphoton microscopy"

As I recall Glyn confirmed with someone here recently that OBJ was not involved in the Nano-patch developement project at the University of Queensland, so I've gone through Dr Prow's papers of which many cite his work with the Nano-patch, and by way of elimination provide only those citations most recently published which do not appear to involve either the Nano-patch or its inventor:

* This of course still shouldn't imply that any of the following is definitely connected to OBJ:

Nanoparticles and microparticles for skin drug delivery

Flexible Nanosomes (SECosomes) Enable Efficient siRNA Delivery in Cultured Primary Skin Cells and in the Viable Epidermis of Ex Vivo Human Skin

Analysis of the metabolic deterioration of ex vivo skin from ischemic necrosis through the imaging of intracellular NAD(P)H by multiphoton tomography and fluorescence lifetime imaging microscopy

Nature Network - Publications
___

Knee Guard
"The Company’s Musculoskeletal Patch program moved another step forward during the quarter with market research data indicating a commercial opportunity for the Company in both the retail analgesic and sporting markets. New product concepts are now being tested internationally prior to the Company determining the level of investment required to meet the commercial challenge in each category."

This quarter has seen further progression with the 'internal' Musculoskeletal Patch program, however the expenditure, as reported for this quarter appears to be significantly low, so I continue to believe that the board await some form of cash injection which is anticipated from partner negotiations, (which are unrelated to this project) before any of the major expenditure is required?

Hygiene
"The Company’s work in deep hygiene applications continued during the quarter with further encouraging results from the University of Bradford (UK) regarding disinfectant penetration into nonpermeable surfaces under the influences of Field in Motion (FIM). This is early work however the Company is encouraged by progress to date."

Everytime I attempt to research "hygiene applications" associated to programs at the University of Bradford, it takes me straight down the "way off the mark" paths I've followed before, so I'm sticking with other confirmed connections, ie, Dr Britland, Centre for Skin Sciences and other scientists and/or programs related to the topic of "drug delivery"

The following names are listed as sponsors on the Centre of Skin Sciences website, although Dr britland's most recently published work cited Reckitt Benckiser as the fundor, and his Biography link below also acknowledges Wellcome Trust as a regular funding partner to his laboratory...

* Boots
* BASF
* Unilever
* L'Oreal UK

Steve Britland

Centre for Skin Sciences - Jamshed Anwar

Interaction of ethanol with biological membranes: the formation of non-bilayer structures within the membrane interior and their significance
___

Hi Pman,

"once the scope is defined then discussions lean towards financial and investment agreements as one cannot determine the cost of a project without knowing the scope."

Was Glyn making a reference to "Product Scope" or "Project Scope"
___

Hi Bluebush,

"the hygiene thing has got me confused "disinfectant penetration into nonpermeable surfaces" I would have thought that (by definition) non-permeable surfaces are not permeable, anyway I'm sure that's a typo?"

Thank god, I'm not the only one going crazy with the Bradford/hygiene lead...

Here's a crazy thought: I know that Bradford are collaborating with Dyson... but OBJ and Dyson?